CEACAM5 and cancer: Lactate dehydrogenase (LDH) levels, complete blood count, carcinoembryonic antigen (CEA), glycated hemoglobin (HbA1c), and C-reactive protein (CRP) are accessible biomarkers, forming part of the standard patient assessment; they could be predictive factors for cancer in diabetic patients and can guide the oncologist in terms of patient prognosis at the onset of treatment [4].